Literature DB >> 4015695

Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil.

K W Renton.   

Abstract

Diltiazem and verapamil were found to be inhibitors of the cytochrome P-450-dependent biotransformation of drugs. Diltiazem and verapamil competitively inhibited the N-demethylation of aminopyrine in hepatic microsomes with Ki values of 100 and 140 microM respectively. Both diltiazem and verapamil were N-demethylated themselves by hepatic microsomes with Km values of 62 and 145 microM respectively. Both drugs also interacted directly with cytochrome P-450 as measured by difference spectra. Diltiazem caused a type I spectral change and verapamil caused a reverse type I spectral change. No metabolic intermediate complexes could be demonstrated for either drug. Inhibition also occurred in vivo as both drugs could prolong pentobarbital-induced sleeping times in mice at doses comparable to those used in man. These results suggest that diltiazem and verapamil may have the potential to cause drug interactions involving inhibition of drug biotransformation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4015695     DOI: 10.1016/0006-2952(85)90541-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  26 in total

1.  The effect of three different oral doses of verapamil on the disposition of theophylline.

Authors:  K A Stringer; J Mallet; M Clarke; J A Lindenfeld
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Pharmacokinetic drug interactions with cyclosporin (Part II).

Authors:  G C Yee; T R McGuire
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

3.  An examination of a possible pharmacokinetic interaction between nifedipine and antipyrine.

Authors:  T Edeki; A Johnston; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein.

Authors:  A G Pinto; J Horlander; N Chalasani; M Hamman; A Asghar; D Kolwankar; S D Hall
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

Review 5.  Pharmacokinetic interactions with calcium channel antagonists (Part II).

Authors:  K D Schlanz; S A Myre; M B Bottorff
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

Review 6.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

7.  Calcium channel antagonists and cyclosporine metabolism: in vitro studies with human liver microsomes.

Authors:  J F Tjia; D J Back; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

8.  Nifedipine, verapamil and cyclosporin A pharmacokinetics in children.

Authors:  M R Ogborn; J F Crocker; P C Grimm
Journal:  Pediatr Nephrol       Date:  1989-07       Impact factor: 3.714

9.  The effect of oral verapamil therapy on antipyrine clearance.

Authors:  D O Rumiantsev; V K Piotrovskii; O S Riabokon; I D Slastnikova; E V Kokurina; V I Metelitsa
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

10.  Pharmacokinetic interaction between cyclosporin and diltiazem.

Authors:  J Brockmöller; H H Neumayer; K Wagner; W Weber; G Heinemeyer; H Kewitz; I Roots
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.